GlassScriptPhysician profile
Amanda Dee Flores
NPI 1083394977
$2,296.18
in general payments reported to CMS, 2019-2025
19 companies · $817 in 2025
The $817 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $733 · 2024: $746 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,173.19 |
| Education | $122.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $648.16 | 2023-2025 | Airsupra, Fasenra, Tezspire |
| Genentech USA, INC. | $281.64 | 2024-2025 | Xolair |
| Amgen INC. | $227.95 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $200.13 | 2023-2025 | Cuvitru, Takhzyro, Glassia |
| Pharming Healthcare, INC. | $196.65 | 2023-2024 | Ruconest |
| Janssen Pharmaceuticals, INC | $162.11 | 2025 | Invega Sustenna, Invega Trinza |
| Regeneron Healthcare Solutions, INC. | $112.37 | 2023-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $88.99 | 2025 | |
| Glaxosmithkline, LLC. | $75.33 | 2023-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Ars Pharmaceuticals Operations, INC. | $65.97 | 2025 | Neffy |
| Genzyme Corporation | $52.49 | 2025 | |
| Incyte Corporation | $33.64 | 2023 | Opzelura |
| Novartis Pharmaceuticals Corporation | $33.35 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $24.62 | 2024 | Orladeyo |
| Csl Behring | $23.92 | 2023 | Hizentra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $20.31 | 2023 | Gamunex-C |
| Mylan Specialty L.P. | $19.52 | 2023 | Yupelri |
| Pfizer INC. | $16.12 | 2023 | |
| Merck Sharp & Dohme LLC | $12.91 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.